Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2024-03-13 Investor Presentation
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 13, 2024, by Chromocell Therapeutics Corporation. It reports on a Regulation FD Disclosure regarding a presentation at the Sidoti Small Cap Conference. The document includes a reference to presentation materials (Exhibit 99.1) used at the conference and states that these materials will be posted on the company's website. The content focuses on business updates and pipeline progress, typical of investor presentations. There are no financial statements or detailed financial analysis included in the text, only a description of the presentation and forward-looking statements. The document is not an earnings release, annual or interim report, or audit report. It is a current report disclosing a presentation event and furnishing the presentation materials. Therefore, the filing best fits the category of Investor Presentation (IP). The document length (7038 characters) supports that it is more than a brief announcement but not a full financial report. Confidence is high given the clear identification of the presentation and the nature of the disclosure.
2024-03-13 English
Director's Dealing 2024
Director's Dealing
2024-03-12 English
SC 13G
Major Shareholding Notification
2024-03-04 English
SC 13G
Major Shareholding Notification
2024-03-01 English
SC 13G
Major Shareholding Notification
2024-03-01 English
SC 13G
Major Shareholding Notification
2024-03-01 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.